# Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

> **NCT00071994** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 59 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** gefitinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00071994
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-05
- **Final completion:** —
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2013-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071994, "Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00071994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*